homepage-top-section

If approved, venglustat would be the first treatment in the US to address the neurological symptoms of GD3, which currently have no targeted therapies. The decision is anticipated

This move strengthens vaccine supply resilience in Colombia and creates a pathway for SK bioscience’s expansion into Latin America. The Colombian Ministry of Health and Social Protection, National

The recommendation covers the use of the therapy in combination with cetuximab and Folfox as a first-line treatment option for adult patients with BRAFV600E-mutant mCRC. This represents a

First announced last month, the move aims to advance Gilead’s oncology portfolio. Under the agreement, the company acquired all outstanding equity of Tubulis for $3.15bn upfront on a

The initiative will embed agentic capabilities throughout BMS’ research, clinical, manufacturing, commercial, and corporate operations. It aims to shift from basic conversational AI towards advanced agentic tools within

The move aims to allow pharmaceutical and biotechnology researchers to use AI more effectively by leveraging enhanced bioinformatics tools and curated knowledge bases. The integration also aims to

Helicons are stabilised, cell-penetrant alpha-helical peptides engineered to interact with intracellular protein targets, including those with flat surfaces unsuitable for traditional small molecule engagement. The partnership will investigate

Data from the DESTINY-Breast11 and DESTINY-Breast05 Phase III trials support these approvals. They cover the use of Enhertu in both the neoadjuvant and adjuvant treatment settings for adult

Affecting adults and children, this rare, progressive, genetic disorder impacts both bone and muscle health due to the body’s inability to retain sufficient phosphorus, a mineral essential for